 influence autologous lymphokine-activated killer cell infusions toxicity antitumor effect repetitive cycles patients refractory malignancies protocol addition ex vivo-activated autologous lymphokine-activated killer LAK cells tolerable regimen weekly cycles human recombinant continuous infusion days/week Sixteen patients induction month therapy partial response stable disease progressive disease patients clinical toxicity completion induction month therapy patients therapy Significant clinical toxicities decreased performance status gain catheter-related thromboses infectious complications fever hypotension dyspnea hypoxemia oxygen addition LAK cell infusions regimen noticeable change antitumor response rate severe toxicity